[Safety ov benign prostatic hyperplasia treatment with alpha-adrenoblocker dalphas]

Area of Science:

• Urology
• Pharmacology
• Internal Medicine

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men.
• Urinary problems associated with BPH significantly impact quality of life.
• Effective and safe treatment options for BPH are continuously sought.

Purpose of the Study:

• To assess the safety and effectiveness of d-alpha-tocopherol (dalphas-retard) in patients with BPH.
• To evaluate the incidence and nature of side effects associated with dalphas-retard treatment.
• To determine the tolerability of dalphas-retard in a clinical setting.

Main Methods:

• A study involving 940 patients diagnosed with benign prostatic hyperplasia and related urinary issues.
• Patients received d-alpha-tocopherol (dalphas-retard) at a dosage of 5-10 mg/day for a duration of 12 weeks.
• Outcomes and side effects were monitored throughout the treatment period, with final assessments conducted on 881 patients.

Main Results:

• The study assessed 881 patients who completed the 12-week treatment course.
• A low incidence of treatment discontinuation due to side effects was observed (1.9%, 18 patients).
• Overall, 4% of patients (38 individuals) experienced side effects during the study.

Conclusions:

• D-alpha-tocopherol (dalphas-retard) appears to be a safe and well-tolerated treatment option for benign prostatic hyperplasia.
• The drug demonstrated a favorable safety profile with a low rate of adverse events and discontinuations.
• Further research may explore the long-term efficacy of dalphas-retard in managing BPH symptoms.